Systematic review and network meta-analysis of overall survival comparing 3 mg/kg ipilimumab with alternative therapies in the management of pretreated patients with unresectable stage III or IV melanoma.
Abstract
To compare the overall survival (OS) of patients treated with 3 mg/kg ipilimumab versus alternative systemic therapies in pretreated unresectable stage III or IV melanoma patients.Citation
Systematic review and network meta-analysis of overall survival comparing 3 mg/kg Ipilimumab with alternative therapies in the management of pretreated patients with unresectable stage III or IV melanoma. 2012, 17 (11):1376-85 OncologistJournal
The OncologistDOI
10.1634/theoncologist.2011-0427PubMed ID
23024154Type
ArticleLanguage
enISSN
1549-490Xae974a485f413a2113503eed53cd6c53
10.1634/theoncologist.2011-0427